Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Modulatory Role of Blood-Brain-Barrier and Enzymatic Activity in an Innovative Human Model of Anticholinergic Drug Induced Dementia

Award Number: R44AG071386
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/15/2021
PERIOD OF PERFORMANCE END DATE: 04/30/2027

Group Awards By:

View Award Description

Modulatory Role of Blood-Brain-Barrier and Enzymatic Activity in an Innovative Human Model of Anticholinergic Drug Induced Dementia - Project Summary/Abstract The burden associated with polypharmacy and inappropriate drug use is the third leading cause of death in the USA. With advanced age, providing medical care can present challenges as these patients are at risk for comorbidities like Alzheimer’s Disease (AD) and have the largest burden of illness. The resulting prescription cascade increases the risk of multi-drug interactions on enzymatic systems (such as the Cytochrome P450 superfamily) used to metabolize many drugs with anticholinergic properties. There is the unmet need of having proper approaches and innovative tools to identify not only drugs but also drug regimens associated with the highest risk of drug-related adverse events (ADEs). Medications with anticholinergic properties have frequently been cited in the literature as a major cause for an increase in ADEs. Hence, innovative approaches and tools developed to address these situations should consider not only individual drug pharmacological properties but account for conditions associated with the impact of multi-drug intake and interactions. After the success of the Phase II grant, we seek to use Hesperos’ patented multi-organ functional systems to investigate drug-induced dementia and AD in terms of deficits in basic information processing in the presence of anticholinergic drugs in collaboration with GalenusRx and our AD consultant, Dr. Dave Morgan at MSU. GalenusRx has created basic and clinical algorithms that help quantitatively score the risk of ADEs, including an assessment of drug anticholinergic properties and multi-drug interactions, with a special look at competitive inhibition utilizing the APPRAISE platform. Increased knowledge on these factors through the conduct of proposed studies with Hesperos’ experimental systems shall improve the predictivity of risk stratification possibilities, help decrease the risk of ADEs in elderly patients, decrease hospitalizations, and reduce overall medical costs. The value of GalenusRx’s risk stratification strategy has been demonstrated by publications in peer-review journals and filing of patents. There are few in vitro models that examine anticholinergic drug properties in the CNS while assessing their association between anticholinergic burden and risk of dementia, including AD. Thus, a preclinical screening model based on functional assays composed of normal and AD mutant human cells to evaluate the effects of anticholinergic drugs in conditions mimicking aspects of AD enables a platform for understanding multiplicative effects and to inform GalenusRx’s clinical models. No other models assessing the anticholinergic burden of drugs take into account their dose, duration of treatment and concomitant drug administration leading to a change in their disposition. Changes in Long-term Potentiation will be used as the cognitive readout as it is a functional measurement known to correlate with changes in memory and learning. The integration of this neuronal module with a system that includes a blood-brain-barrier and a liver with functional enzymatic systems would allow testing of combinational therapeutics and variability in their metabolic disposition due to expected multi-drug interactions impacting drug metabolism systems as observed in patients with polypharmacy.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $1,500,000 )
2025	2025	HESPEROS, INC	12501 RESEARCH PKWY STE 100	ORLANDO	FL	32826	ORANGE	USA	Aging Research	001	3	8/8/2025	COMPETING CONTINUATION	$1,500,000
2025	2022	HESPEROS, INC	12501 RESEARCH PKWY STE 100	ORLANDO	FL	32826	ORANGE	USA	Aging Research	000	2	12/5/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $1,500,000

Issue Date FY: 2022 ( Subtotal = $1,065,041 )
2022	2022	HESPEROS, INC.	12501 RESEARCH PKWY STE 100	ORLANDO	FL	32826	ORANGE	USA	Aging Research	000	2	8/16/2022	NON-COMPETING CONTINUATION	$902,299
2022	2022	HESPEROS, INC.	12501 RESEARCH PKWY STE 100	ORLANDO	FL	32826	ORANGE	USA	Aging Research	001	2	8/18/2022	SUPPLEMENT FOR EXPANSION	$162,742
														Subtotal = $1,065,041

Issue Date FY: 2021 ( Subtotal = $902,320 )
2021	2021	HESPEROS, INC.	12501 RESEARCH PKWY STE 100	ORLANDO	FL	32826	ORANGE	USA	Aging Research	000	1	8/10/2021	NEW	$902,320
														Subtotal = $902,320

Grand Total All Awards = $3,467,361

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Modulatory Role of Blood-Brain-Barrier and Enzymatic Activity in an Innovative Human Model of Anticholinergic Drug Induced Dementia

Award Number: R44AG071386

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/15/2021

PERIOD OF PERFORMANCE END DATE: 04/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer